Redeye views Calmarks Q2 report as undramatic, and commercialization of its tests seems to go as planned. In the quarter, Calmark received its initial orders from several markets and gave updates regarding current operations.
ANNONS
Redeye views Calmarks Q2 report as undramatic, and commercialization of its tests seems to go as planned. In the quarter, Calmark received its initial orders from several markets and gave updates regarding current operations.